Showing results (1881-1890 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 4, 2011
Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in ratsPius Maliakal, Maen Abdelrahim, Umesh T Sankpal, et al.
Investigational New Drugs|December 2, 2010
Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathwayChung Soo Lee, Eun-Ra Jang, Yun Jeong Kim, et al.
Investigational New Drugs|December 2, 2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancerStefan Madajewicz, David M Waterhouse, Paul S Ritch, et al.
Investigational New Drugs|August 27, 2010
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteersYazdi K Pithavala, Warren Tong, Janessa Mount, et al.
Investigational New Drugs|June 23, 2010
Ultraviolet recall dermatitis reaction with sorafenibNicolas Magné, Cyrus Chargari, Pierre Auberdiac, et al.
Investigational New Drugs|June 23, 2010
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposideCatherine J Drummond, Graeme J Finlay, Laura Broome, et al.
Investigational New Drugs|September 22, 2010
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsMatthew D Galsky, Daniel D Von Hoff, Marcus Neubauer, et al.
Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.
Investigational New Drugs|November 4, 2010
Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cellsKatja Ester, Fran Supek, Kristina Majsec, et al.
Investigational New Drugs|November 5, 2010
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trialsNicolas Penel, Alain Duhamel, Antoine Adenis, et al.
Pageof 372